Abstract
With its superior sensitivity and specificity, cardiac troponin has gradually replaced other cardiac enzymes, and is now the biomarker of choice in making the critical diagnosis of an acute coronary syndrome (ACS). The early stratification of risk from unstable angina to non-ST segment elevation myocardial infarction (NSTEMI), is crucial in the timing and treatment of the ACS. Troponin elevations have also been shown to be powerfully prognostic in a variety of clinical settings and because of this predictive value, may be useful in determining benefit of various clinical interventions. However, inherent in this improved sensitivity and specificity of the measurement tools is the inclusion of non-ACS patients with abnormal troponin measurements. Increased understanding of the alternative diagnoses associated with elevated troponins as well as assays which allow more rapid and accurate diagnosis of ACS, are needed to further improve patient care. Clinical trials of risk stratification controlling for concomitant associated diagnoses including renal insufficiency, pulmonary embolism, atrial fibrillation and congestive heart failure will provide data to optimize this tool.
Keywords: Troponin, ACS, cardiac biomarkers, chest pain, NSTEMI
Cardiovascular & Hematological Disorders-Drug Targets
Title: Moving Troponin Testing into the 21st Century: Will Greater Sensitivity Be Met with Greater Sensibility?
Volume: 8 Issue: 2
Author(s): Lisa S. Rosenbaum and James L. Januzzi
Affiliation:
Keywords: Troponin, ACS, cardiac biomarkers, chest pain, NSTEMI
Abstract: With its superior sensitivity and specificity, cardiac troponin has gradually replaced other cardiac enzymes, and is now the biomarker of choice in making the critical diagnosis of an acute coronary syndrome (ACS). The early stratification of risk from unstable angina to non-ST segment elevation myocardial infarction (NSTEMI), is crucial in the timing and treatment of the ACS. Troponin elevations have also been shown to be powerfully prognostic in a variety of clinical settings and because of this predictive value, may be useful in determining benefit of various clinical interventions. However, inherent in this improved sensitivity and specificity of the measurement tools is the inclusion of non-ACS patients with abnormal troponin measurements. Increased understanding of the alternative diagnoses associated with elevated troponins as well as assays which allow more rapid and accurate diagnosis of ACS, are needed to further improve patient care. Clinical trials of risk stratification controlling for concomitant associated diagnoses including renal insufficiency, pulmonary embolism, atrial fibrillation and congestive heart failure will provide data to optimize this tool.
Export Options
About this article
Cite this article as:
Rosenbaum S. Lisa and Januzzi L. James, Moving Troponin Testing into the 21st Century: Will Greater Sensitivity Be Met with Greater Sensibility?, Cardiovascular & Hematological Disorders-Drug Targets 2008; 8 (2) . https://dx.doi.org/10.2174/187152908784533711
DOI https://dx.doi.org/10.2174/187152908784533711 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Sirtuin Inhibitor Nicotinamide Enhances Neuronal Cell Survival During Acute Anoxic Injury Through AKT, BAD, PARP, and Mitochondrial Associated "Anti-Apoptotic" Pathways
Current Neurovascular Research Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Single Emulsion-Solvent Evaporation Technique and Modifications for the Preparation of Pharmaceutical Polymeric Nanoparticles
Recent Patents on Drug Delivery & Formulation Cell and Gene Therapies in Cardiovascular Disease with Special Focus on the No Option Patient
Current Gene Therapy Prevalence of Analgesic Use and Pain in People with and without Dementia or Cognitive Impairment in Aged Care Facilities: A Systematic Review and Meta-Analysis
Current Clinical Pharmacology Recent Applications of Benzimidazole as a Privileged Scaffold in Drug Discovery
Mini-Reviews in Medicinal Chemistry Diabetes Mellitus and Renal Function: Current Medical Research and Opinion
Current Diabetes Reviews Ca2+-Handling Proteins and Heart Failure: Novel Molecular Targets?
Current Medicinal Chemistry The Potential Impact of Sirtuin 1 Protein on Premature Ovarian Insufficiency
Current Proteomics Traditional and Novel Risk Factors of Diabetic Retinopathy and Research Challenges
Current Medicinal Chemistry A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design Safety Issues of Vitamin D Supplementation
Anti-Cancer Agents in Medicinal Chemistry Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets Pleiotropic Effects of HDL: Towards New Therapeutic Areas for HDL-Targeted Interventions
Current Molecular Medicine Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets Glucagon Like Peptides-1 Modulators as Newer Target for Diabetes
Current Drug Targets Late Life Depression: A Diagnostic and Pharmacological Review
Current Psychopharmacology Drug Discoveries Towards Kv1.5 Potassium Channel
Current Topics in Medicinal Chemistry ICT for Telemedicine and Health Care Innovation
Recent Patents on Biomedical Engineering (Discontinued) Targeting CSC-Related miRNAs for Cancer Therapy by Natural Agents
Current Drug Targets